Tango Therapeutics (TNGX) Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance

Simply Wall St.01-15

Tango Therapeutics (TNGX) is back in focus after announcing a leadership reshuffle, with founding CEO Dr. Barbara Weber retiring as chief executive and board member Dr. Malte Peters stepping in as CEO...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603681674?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-01-15 11:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603681674","market":"sg","top_or_hot":-1,"title":"Tango Therapeutics (TNGX) Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance","media":"Simply Wall St.","content":"<div>\n<p>Tango Therapeutics (TNGX) is back in focus after announcing a leadership reshuffle, with founding CEO Dr. Barbara Weber retiring as chief executive and board member Dr. Malte Peters stepping in as CEO...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-check-after-leadership-res\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tango Therapeutics (TNGX) Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTango Therapeutics (TNGX) Valuation Check After Leadership Reshuffle And Strong Recent Share Price Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-15 11:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-check-after-leadership-res><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tango Therapeutics (TNGX) is back in focus after announcing a leadership reshuffle, with founding CEO Dr. Barbara Weber retiring as chief executive and board member Dr. Malte Peters stepping in as CEO...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-check-after-leadership-res\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-check-after-leadership-res","article_id":"2603681674","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tngx/tango-therapeutics/news/tango-therapeutics-tngx-valuation-check-after-leadership-res","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603681674","pubTimestamp":1768447869,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Tango Therapeutics (TNGX) is back in focus after announcing a leadership reshuffle, with founding CEO Dr. Barbara Weber retiring as chief executive and board member Dr. Malte Peters stepping in as CEO and president.\nSee our latest analysis for Tango Therapeutics.\nThe leadership changes arrive after a strong run, with the 1 month share price return at 35.86% and the 1 year total shareholder return very large, suggesting momentum has been building around Tango Therapeutics at a share price of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TNGX":"Tango Therapeutics Inc."},"translate_title":"Tango Therapeutics(TNGX)领导层改组和近期股价表现强劲后的估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNGX":1.5},"content_text":"Tango Therapeutics (TNGX) is back in focus after announcing a leadership reshuffle, with founding CEO Dr. Barbara Weber retiring as chief executive and board member Dr. Malte Peters stepping in as CEO and president. See our latest analysis for Tango Therapeutics. The leadership changes arrive after a strong run, with the 1 month share price return at 35.86% and the 1 year total shareholder return very large, suggesting momentum has been building around Tango Therapeutics at a share price of $12.39. If this kind of executive reshuffle has you looking across the sector, it could be a useful time to scan other healthcare stocks that might fit your watchlist next. With the stock up sharply over the past year and trading close to an average analyst price target of $13.25, the real question now is whether Tango Therapeutics is still mispriced or if the market is already assuming stronger future growth. AdvertisementPrice-to-Sales of 25.1x: Is it justified? Tango Therapeutics trades at a P/S of 25.1x, which sits well above several benchmarks, so the current US$12.39 share price already bakes in a rich revenue multiple. The P/S ratio compares the company’s market value to its revenue and is often used for early stage or unprofitable biotechs where earnings are still negative. For a business like Tango, which reported US$66.501m of revenue and a loss of US$100.515m, this metric becomes a primary shorthand for how much investors are willing to pay for each dollar of current sales. Here, the market is assigning a P/S of 25.1x, while the peer group sits around 9.3x and the broader US Biotechs industry average is 12.5x. In addition, the estimated fair P/S ratio stands at just 1.9x, a level that implies a much lower valuation that some investors may watch as a potential reference point if sentiment cools. Explore the SWS fair ratio for Tango Therapeutics Result: Price-to-Sales of 25.1x (OVERVALUED) However, that rich 25.1x P/S and ongoing US$100.515m loss mean any clinical or partnership setbacks could quickly challenge the current optimism around Tango Therapeutics. Find out about the key risks to this Tango Therapeutics narrative.  Build Your Own Tango Therapeutics Narrative If you think this view misses something or prefer to work from the raw numbers yourself, you can build a custom thesis in just a few minutes, starting with Do it your way. A great starting point for your Tango Therapeutics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision. Looking for more investment ideas? If you want to push your research further, use these focused stock lists to spot opportunities faster and keep your watchlist working hard for you.  Zero in on potential value by scanning these 884 undervalued stocks based on cash flows that may offer more attractive price tags relative to their cash flows. Explore these 25 AI penny stocks that are exposed to artificial intelligence themes across different parts of the market. Position your portfolio for income potential through these 12 dividend stocks with yields > 3% that already offer yields above 3%.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tango Therapeutics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603681674","isCrawlerRequest":true}